Mr. Stefano Picone reports

CPOINT CAPITAL CORP. ANNOUNCES CHANGES TO HOLDINGS IN CONAVI MEDICAL CORP.

On April 23, 2025, CPoint Capital Corp. and its affiliate, Juno Pharmaceuticals LP, acquired 1,875,000 common shares in the capital of Conavi Medical Corp. (625,000 of which are held by CPoint and 1.25 million of which are held by Juno), in connection with a public offering of the company by way of a short form prospectus dated April 15, 2025. CPoint and its affiliate, Juno, purchased the common shares at a price of 40 cents per common share for total consideration of $750,000.

Prior to this acquisition and as reported in the last early warning report of CPoint, CPoint and its affiliate Juno beneficially owned 9,985,175 common shares and 8,586,181 common share purchase warrants, representing approximately 22.57 per cent of the outstanding common shares on a non-diluted basis and 35.15 per cent of the outstanding common shares on a partially diluted basis (assuming the exercise of CPoint and Juno's convertible securities). After this acquisition (and after giving effect to the other treasury issuances of common shares by the company in the public offering), CPoint and its affiliate, Juno, beneficially own 11,860,175 common shares and 8,586,181 common share purchase warrants, representing approximately 15.45 per cent of the outstanding common shares on a non-diluted basis and 23.96 per cent of the outstanding common shares on a partially diluted basis (assuming the exercise of CPoint and Juno's convertible securities).

The securities noted above are held for investment purposes. CPoint and its affiliate, Juno, have a long-term view of the investment and may acquire additional securities, including either on the open market or through private acquisitions, or sell the securities, including either on the open market or through private dispositions, in the future, depending on market conditions, reformulation of plans and/or other relevant factors.

The company is located at 293 Lesmill Rd., Toronto, Ont., M3B 2V1. A copy of the early warning report with respect to the foregoing will appear on the company's profile on SEDAR+ and may also be obtained by contacting Stefano Picone, chief financial officer of the company, at 416-483-0100. CPoint is a corporation existing under the laws of Ontario and, for the purposes of National Instrument 62-103 early warning reporting, its address is 555 Richmond St. W, Suite 512, Toronto, Ont., M5V 3B1.